Company intelligence / Profile preview

Biodep

Jiangyin, Jiangsu, China

Ownership: Private
Employees: ~300
Development stage: Other

Overview

Biodep provides high-potency probiotic and postbiotic strains that are clinically certified for applications in intestinal health, immune regulation, and anti-aging. The company conducts research in collaboration with international institutions to validate the efficacy of its strains through animal and clinical studies.

Therapeutic areas: PsychiatryImmunologyOtherGastroenterology
Modalities: Microbial therapyProbioticsPostbiotics
Industry: Biotech

Partnerships

Rutgers UniversityUniversity of QueenslandFudan University Shanghai Cancer CenterNanjing Agricultural UniversityCMB International

Beyond the preview

Go deeper on Biodep.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biodep.

Explore the full profile